Related Experiment Videos
[Febrile reaction to D-penicillamine]
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris
|March 8, 1984
Abstract:
Two personal observations of febrile reaction to D-penicillamine in patients with rheumatoid arthritis provide the opportunity for recalling the clinical presentation which is fairly uniform. The physiopathological mechanism is still unknown. In Wilson disease, progressive reintroduction of the drug may be successful.
Insights
D-penicillamine can cause a uniform febrile reaction in rheumatoid arthritis patients. Progressive reintroduction may be successful in Wilson disease cases, though the mechanism remains unknown.
Area of Science:
- Rheumatology
- Pharmacology
- Hepatology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- D-penicillamine is a chelating agent used in treating RA and Wilson disease.
- Febrile reactions are a known potential adverse effect of D-penicillamine.
Observation:
- Two patients with rheumatoid arthritis experienced a febrile reaction to D-penicillamine.
- The clinical presentation of the febrile reaction was notably uniform across both patients.
Findings:
- The exact physiopathological mechanism underlying D-penicillamine-induced fever remains undetermined.
- Despite the febrile reaction, successful reintroduction of D-penicillamine was achieved in a patient with Wilson disease through progressive administration.
Implications:
- Understanding the uniform presentation of febrile reactions aids in clinical recognition.
- Further research into the mechanism of D-penicillamine fever is warranted.
- Careful, progressive reintroduction of D-penicillamine may be a viable strategy in specific patient populations, such as those with Wilson disease.